Lehrnbecher, Thomas M.Thomas M.LehrnbecherSack, UlrichUlrichSackSpeckmann, CarstenCarstenSpeckmannGroll, Andreas H.Andreas H.GrollBoldt, AndreasAndreasBoldtSiebald, BenjaminBenjaminSiebaldHettmer, SimoneSimoneHettmerDemmerath, Eva-MariaEva-MariaDemmerathReemtsma, JudithJudithReemtsmaSchenk, BarbaraBarbaraSchenkCiesek, SandraSandraCiesekKlusmann, Jan-HenningJan-HenningKlusmannJassoy, ChristianChristianJassoyHoehl, SebastianSebastianHoehl2023-08-112023-08-112023https://publica.fraunhofer.de/handle/publica/44803510.1093/cid/ciac5702-s2.0-8514778333535901198Our study in 21 pediatric cancer patients demonstrates that 3 doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA vaccine (BioNTech/Pfizer) elicited both humoral and cellular immunity in most patients during chemotherapy. Immunity was stronger in children with solid tumors and during maintenance therapy compared to those with hematological malignancies or during intensive chemotherapy.encancerchildSARS-CoV-2vaccinationjournal article